Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review
CC Murphy, LK Bartholomew, MY Carpentier… - Breast cancer research …, 2012 - Springer
Adjuvant hormonal therapy significantly improves long-term survival of breast cancer
patients with hormone receptor-positive disease. Despite the proven clinical efficacy of …
patients with hormone receptor-positive disease. Despite the proven clinical efficacy of …
Novel strategies on personalized medicine for breast cancer treatment: an update
Breast cancer is the most common cancer type among women worldwide. With breast
cancer patients and survivors being reported to experience a repertoire of symptoms that are …
cancer patients and survivors being reported to experience a repertoire of symptoms that are …
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study
CM Kelly, DN Juurlink, T Gomes, M Duong-Hua… - Bmj, 2010 - bmj.com
Objective To characterise whether some selective serotonin reuptake inhibitor (SSRI)
antidepressants reduce tamoxifen's effectiveness by inhibiting its bioactivation by …
antidepressants reduce tamoxifen's effectiveness by inhibiting its bioactivation by …
CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
Background Adjuvant tamoxifen therapy is effective for postmenopausal women with
endocrine-responsive breast cancer. Cytochrome P450 2D6 (CYP2D6) enzyme metabolizes …
endocrine-responsive breast cancer. Cytochrome P450 2D6 (CYP2D6) enzyme metabolizes …
CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
Background Adjuvant tamoxifen therapy substantially decreases the risk of recurrence and
mortality in women with hormone (estrogen and/or progesterone) receptor–positive breast …
mortality in women with hormone (estrogen and/or progesterone) receptor–positive breast …
A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular …
Today, in silico studies and trial simulations already complement experimental approaches
in pharmaceutical R&D and have become indispensable tools for decision making and …
in pharmaceutical R&D and have become indispensable tools for decision making and …
Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk
PURPOSE Nonadherence to long-term treatments is often under-recognized by physicians
and there is no gold standard for its assessment. In breast cancer, nonadherence to …
and there is no gold standard for its assessment. In breast cancer, nonadherence to …
CYP2D6 Genotype and Adjuvant Tamoxifen: Meta‐Analysis of Heterogeneous Study Populations
MA Province, MP Goetz, H Brauch… - Clinical …, 2014 - Wiley Online Library
The International Tamoxifen Pharmacogenomics Consortium was established to address
the controversy regarding cytochrome P450 2D6 (CYP2D6) status and clinical outcomes in …
the controversy regarding cytochrome P450 2D6 (CYP2D6) status and clinical outcomes in …
Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer
VO Dezentjé, NJC van Blijderveen… - Journal of Clinical …, 2010 - ascopubs.org
Purpose The use of cytochrome P450 2D6–inhibiting drugs (CYP2D6 inhibitors) during
tamoxifen treatment leads to a decrease in plasma concentration of endoxifen, the major …
tamoxifen treatment leads to a decrease in plasma concentration of endoxifen, the major …
Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen
Purpose To review recent pharmacogenomics studies on breast cancer patients undergoing
tamoxifen therapy, highlighting how our knowledge on cytochrome P450 2D6 (CYP2D6) can …
tamoxifen therapy, highlighting how our knowledge on cytochrome P450 2D6 (CYP2D6) can …